As of 2025-05-23, the EV/EBITDA ratio of Ligand Pharmaceuticals Inc (LGND) is -52.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LGND's latest enterprise value is 1,904.91 mil USD. LGND's TTM EBITDA according to its financial statements is -36.61 mil USD. Dividing these 2 quantities gives us the above LGND EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.0x - 13.4x | 13.2x |
| Forward P/E multiples | 15.4x - 36.2x | 19.0x |
| Fair Price | (26.76) - (22.92) | (28.09) |
| Upside | -126.4% - -122.6% | -127.7% |
| Date | EV/EBITDA |
| 2025-05-21 | -52.64 |
| 2025-05-20 | -53.94 |
| 2025-05-19 | -54.15 |
| 2025-05-16 | -53.74 |
| 2025-05-15 | -53.18 |
| 2025-05-14 | -54.03 |
| 2025-05-13 | -54.31 |
| 2025-05-12 | -54.71 |
| 2025-05-09 | -53.71 |
| 2025-05-08 | -52.67 |
| 2025-05-07 | -54.31 |
| 2025-05-06 | -53.10 |
| 2025-05-05 | -54.69 |
| 2025-05-02 | -56.29 |
| 2025-05-01 | -56.17 |
| 2025-04-30 | -56.54 |
| 2025-04-29 | -57.34 |
| 2025-04-28 | -56.02 |
| 2025-04-25 | -55.60 |
| 2025-04-24 | -55.85 |
| 2025-04-23 | -54.38 |
| 2025-04-22 | -54.76 |
| 2025-04-21 | -53.88 |
| 2025-04-17 | -53.97 |
| 2025-04-16 | -53.78 |
| 2025-04-15 | -54.93 |
| 2025-04-14 | -54.82 |
| 2025-04-11 | -53.60 |
| 2025-04-10 | -52.03 |
| 2025-04-09 | -53.37 |
| 2025-04-08 | -49.60 |
| 2025-04-07 | -51.04 |
| 2025-04-04 | -51.12 |
| 2025-04-03 | -52.99 |
| 2025-04-02 | -55.95 |
| 2025-04-01 | -53.89 |
| 2025-03-31 | -54.06 |
| 2025-03-28 | -55.36 |
| 2025-03-27 | -56.46 |
| 2025-03-26 | -55.61 |
| 2025-03-25 | -56.45 |
| 2025-03-24 | -57.49 |
| 2025-03-21 | -55.64 |
| 2025-03-20 | -56.30 |
| 2025-03-19 | -55.58 |
| 2025-03-18 | -54.62 |
| 2025-03-17 | -56.59 |
| 2025-03-14 | -54.61 |
| 2025-03-13 | -54.31 |
| 2025-03-12 | -55.61 |